Key clinical point: A seizure-detection device worn on the arm showed good sensitivity and reasonable specificity, but no data yet exist on its clinical utility.

Major finding: The Brain Sentinel device had 100% sensitivity while resulting in 1.47 false-positive alarms every 24 hours.

Data source: The pivotal trial for the Brain Sentinel device, which collected detection data from 142 adults and children with a history of seizures.

Disclosures: The study was sponsored by Brain Sentinel, which is developing the device. Dr. Cavazos is a founder of the company, holds stock in the company and is a consultant to the company. Dr. Donner had no disclosures. Dr. Krauss has been a consultant to SK Life Science, Acorda Therapeutics, and Sunovion and has received research support from Upsher-Smith, SK Life Science, UCB, Novartis, and Pfizer.

AES: Development of unobtrusive seizure-detection devices continues